For patients diagnosed with EGFR-mutant NSCLC, this cohort study found that individuals treated with osimertinib had a higher incidence of CTRCEs compared with those who received other EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.